Chong Kun Dang is a new drug developer and challenges to overcome lung cancer tolerance with a dual anti-cancer antibody that simultaneously inhibits hepatocellular growth factor receptor (cMET) and epithelial cell growth factor receptor (EGFR). It is planning to achieve both business performance and R&D performance with bio-new drugs that it is going to challenge for the first time.

Park Kyu-jin, director of Chong Kun Dang, presented the theme of "cMET/EGFR dual antibody development for lung cancer patients" at the 5th Forum on Medical Innovation online event held by the Foundation for Medical Innovation on the 7th. Foundation for Medical Innovation is a non-profit corporation under the Ministry of Scienc